Nicotinell Anijs (Nicotine Polacrilex)

Nicotine Polacrilex, the active ingredient in Nicotinell Anijs, is a nicotine replacement therapy presented as a buccal formulation for buccal use. It helps adult smokers who are trying to quit by providing controlled nicotine delivery that reduces withdrawal symptoms and cravings associated with smoking cessation. Nicotinell Anijs is marketed in the European Union and complies with relevant regulatory standards.

GNH USA supplies Nicotinell Anijs as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Nicotinell Anijs is a nicotine replacement product used to address tobacco‑related dependence and support quitting efforts.

- Smoking cessation: assists adult smokers in quitting by reducing cravings and withdrawal symptoms. - Tobacco dependence: provides a controlled nicotine source to support gradual reduction of tobacco use. - Relapse prevention: helps maintain abstinence after the initial quitting phase.

Common side effects are generally mild and related to the buccal route of administration.

Common Side Effects: - Mouth irritation: mild soreness or tingling in the oral cavity. - Throat irritation: occasional scratchy feeling after use. - Nausea: transient feeling of queasiness. - Increased salivation: excess saliva production. - Dyspepsia: mild indigestion or stomach discomfort. - Hiccups: brief episodes of involuntary diaphragm contraction.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or swelling that may indicate hypersensitivity. - Angioedema: rapid swelling of the face, lips, or tongue requiring immediate medical attention. - Chest pain or arrhythmia: cardiovascular symptoms that should be evaluated promptly. - Severe mouth ulcer: persistent ulceration beyond normal irritation. - Anaphylaxis: rare, life‑threatening systemic allergic response.

Before using Nicotinell Anijs, consider the following safety measures.

- Assess nicotine dependence: determine the appropriate level of nicotine replacement. - Cardiovascular risk: avoid use in patients with recent myocardial infarction or unstable angina. - Pregnancy and lactation: do not use unless the potential benefit outweighs the risk. - Duration of therapy: do not exceed the recommended treatment period without medical supervision. - Concomitant nicotine products: avoid using other nicotine replacement therapies simultaneously. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct heat.

Nicotinell Anijs may interact with other medicines; awareness of potential interactions helps ensure safe use.

Major Interactions (Avoid): - Other nicotine replacement products: combined use can lead to nicotine overdose. - Monoamine oxidase inhibitors (MAOIs): may increase cardiovascular strain. - Certain antihypertensives: concurrent use may potentiate blood pressure changes.

Moderate Interactions (Monitor Closely): - CYP2A6 inhibitors: may alter nicotine metabolism and increase systemic exposure. - Beta‑blockers: nicotine‑induced tachycardia may be masked. - Alcohol: can enhance nicotine cravings and affect tolerability.